• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

IASO Biotherapeutics

Thursday, June 06, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 2
IASO Bio is a biopharmaceutical company focused on creating innovative cell therapies and biologics for cancer and autoimmune diseases based on our fully human antibodies/binders. Our leading asset is FUCASO, a fully human BCMA-targeting autologous CAR-T. FUCASO demonstrated superior efficacy and safety profile in the pivotal study. It has received NDA approval from China’s NMPA for 4L+ multiple myeloma (MM). We are expanding FUCASO to autoimmune diseases. In a basket IIT study, FUCASO demonstrated promising long-lasting efficacy (functional cure) against multiple autoimmune diseases, including MG, IMNM, NMOSD, CIDP, pSS, and RA. Results of the study have been published in leading scientific journals including EMBO Mol. Med., PNAS and Nature’s STTT. We have received IND approval from the FDA on MG, with more IND applications being prepared. We are also testing FUCASO on additional autoimmune diseases in a new IIT study.
IASO Biotherapeutics
Company Website: https://cn.iasobio.com/
Lead Product in Development: FUCASO® (Equecabtagene Autoleucel)

Company HQ City

Shanghai

Company HQ State

Shanghai

Company HQ Country

China

CEO/Top Company Official

Jinhua Zhang

Development Phase of Primary Product

NDA Preparation/In Review
Primary Speaker
Alan Fu, PhD
CFO
IASO
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS